Traws Pharma, Inc. (NASDAQ: TRAW) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $60 thousand versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Traws Pharma, Inc. (TRAW) click here.